Förster-Ruhrmann U, Behrbohm W, Pierchalla G, Szczepek A J, Fluhr J W, Olze H
Klinik für Hals-Nasen-Ohren-Heilkunde, Campus Virchow-Klinikum, Charité - Universitätsmedizin Berlin, Augustenburger Platz 1, 13353, Berlin, Deutschland.
Klinik für Hals-Nasen-Ohren-Heilkunde Campus Mitte, Charité -Universitätsmedizin Berlin, Charitéplatz 1, 13353, Berlin, Deutschland.
HNO. 2019 Aug;67(8):620-627. doi: 10.1007/s00106-019-0668-9.
Analgesic intolerance (AI) is an important diagnostic feature of disease progression in patients with chronic rhinosinusitis (CRS) accompanied by nasal polyps (CRSwNP) and asthma.
The aim of the present study was to determine whether increasing the concentration of acetylsalicylic acid (ASA) used in the diagnostic nasal challenge would improve detection of ASA intolerance (NSAIDs-exacerbated respiratory disease, N‑ERD).
Patients with CRSwNP, asthma, and with (CRSwNP-AAI, n = 20) or without (CRSwNP-A, n = 15) anamnestically reported AI, as well as control subjects with CRS but no nasal polyps, asthma, or AI (n = 15), were challenged nasally with 16 mg ASA and, in case of a negative result, with 25 mg of ASA.
In CRSwNP-AAI subjects, the challenge with 16 mg ASA resulted in detection of AI in 80% of cases; increasing the challenge of ASA to 25 mg improved the AI detection to 95%. In CRSwNP-A subjects, the detection of AI increased from 40% (16 mg ASA) to 53% (25 mg ASA). In the control group, no reaction to nasal ASA challenge was detected. No difference in the diagnosis of positive reactions after provocation was found when using the German vs. the European recommended evaluation criteria. Mild pulmonary symptoms occurred in 2 (10%) CRSwNP-AAI patients following the 16 mg ASA challenge.
In patients with CRSwNP, asthma, and anamnestic AI, nasal provocation can effectively confirm the diagnosis of N‑ERD and can also be recommended for patients with recurrent CRSwNP and asthma but without reported AI. Increasing the ASA challenge to 25 mg increases the overall detection rate.
镇痛不耐受(AI)是伴有鼻息肉(CRSwNP)和哮喘的慢性鼻窦炎(CRS)患者疾病进展的重要诊断特征。
本研究旨在确定增加诊断性鼻激发试验中使用的乙酰水杨酸(ASA)浓度是否能提高对ASA不耐受(非甾体抗炎药加重的呼吸道疾病,N‑ERD)的检测率。
对患有CRSwNP、哮喘且有(CRSwNP-AAI,n = 20)或无(CRSwNP-A,n = 15)既往报告AI的患者,以及患有CRS但无鼻息肉、哮喘或AI的对照受试者(n = 15),用16 mg ASA进行鼻激发试验,若结果为阴性,则用25 mg ASA进行激发试验。
在CRSwNP-AAI受试者中,16 mg ASA激发试验在80%的病例中检测到AI;将ASA激发试验增加到25 mg可将AI检测率提高到95%。在CRSwNP-A受试者中,AI检测率从40%(16 mg ASA)增加到53%(25 mg ASA)。在对照组中,未检测到对鼻ASA激发试验的反应。使用德国与欧洲推荐的评估标准时,激发试验后阳性反应的诊断无差异。16 mg ASA激发试验后,2例(10%)CRSwNP-AAI患者出现轻度肺部症状。
对于患有CRSwNP、哮喘且有既往AI的患者,鼻激发试验可有效确诊N‑ERD,对于复发性CRSwNP和哮喘但无既往AI报告的患者也可推荐使用。将ASA激发试验增加到25 mg可提高总体检测率。